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ABSTRACT 
Background: Long-term trends of cardiovascular complications and death among 
patients with diabetes have not been studied extensively. In addition, we aimed to 
examine the effect of multifactorial risk factor control, as well as optimal levels- and 
relative importance of cardiovascular risk factors, in patients with type 1 diabetes and 
type 2 diabetes. The analyses for patients with diabetes were compared to the general 
population. 
Method:  We used data from the National Diabetes Register along with other 
Swedish health registries and applied different statistical methods such as survival 
analysis and different machine learning models to study our research questions. We 
have focused on the following outcomes: all-cause mortality, acute myocardial 
infarction, coronary heart disease, cardiovascular disease, stroke and heart failure. 
Results: During the period 1998-2014, patients with type 1 diabetes experienced 
approximately 40% greater relative risk reduction for cardiovascular complications, 
compared to matched controls, while patients with type 2 diabetes experienced 
roughly 20% greater risk reduction than their matched controls. A paradoxical finding 
was the lower relative risk reduction of fatal outcomes in patients with diabetes. 
Nevertheless, death and complications have decreased substantially during the last 
two decades.  
Multifactorial risk factor control is associated with significant risk reduction for 
patients with diabetes. Still, patients with type 1 diabetes display 82% and 97% 
elevated risk for myocardial infarction and heart failure, respectively. For type 2 
diabetes, we observed marginally increased risk of death and cardiovascular 
complications in patients with all risk factor at target level. Moreover, there is a 
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monotone relationship between number of risk factor at target level and excess risk of 
outcomes in patients with diabetes. Patients with type 2 diabetes and all risk factors at 
target level had 16% lower relative risk for myocardial infarction, compared to the 
general population. The most important risk factors for cardiovascular complications 
were glycated hemoglobin, physical activity level, systolic blood pressure, low-
density lipoprotein cholesterol, albuminuria, as well as risk factors that in some form 
denote exposure time to the disease (e.g. age, duration of diabetes and age at onset of 
disease). Lower levels for glycated hemoglobin, systolic blood pressure and low-
density lipoprotein cholesterol is associated with reduced risk for cardiovascular 
complications, compared to matched controls. The relative importance analyses 
suggest that risk factors contribute differently between outcomes and type of diabetes. 
Conclusion: Morbidity and mortality have decreased significantly among individuals 
with diabetes. Multifactorial risk factor control is associated with significant risk 
reduction and could perhaps even eliminate the excess risk for cardiovascular disease. 
Lower levels for selected risk factors than recommended target levels is associated 
with lower risk for complications. Heart failure is an emerging diabetes-related 
complication and young individuals with diabetes are at the highest risk of 
complications. 
Keywords: type 1 diabetes mellitus, type 2 diabetes mellitus, cardiovascular 
epidemiology, cardiovascular medicine, cardiology, epidemiology, all-cause 
mortality, cardiovascular disease, coronary heart disease, stroke, heart failure, 
machine learning. 
ISBN 978-91-7833-179-6 (PRINT)  
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SAMMANFATTNING PÅ SVENSKA 
Vi undersökte långtidstrender i komplikationer och mortalitet bland personer med 
diabetes, jämfört med matchade kontroller från den allmänna befolkningen. Vi har 
även studerat möjligheterna att med modern behandling eliminera den förhöjda risken 
för hjärt-kärlsjukdom och förtida död som medförs av diabetes. Slutligen har vi 
studerat den relativa betydelsen av kardiovaskulära riskfaktorer samt vilka nivåer som 
är behäftade med lägst risk för hjärt-kärlsjukdom.  
Vi har huvudsakligen fokuserat på komplikationerna akut hjärtinfarkt, stroke, 
hjärtsvikt, ischemisk hjärtsjukdom, kardiovaskulär sjukdom och död.  
Metod 
Vi har samkört data från Nationella Diabetes Registret med andra kvalitetsregister för 
information om komplikationer, socioekonomiska variabler och dödsorsaker. Vi har 
tillämpat olika statistiska metoder så som överlevnadsanalys och olika 
maskininlärnings metoder för att studera ovanstående frågeställningar.  
Resultat 
Under perioden 1998-2014 observerade vi att patienter med typ 1 diabetes upplevde 
40 % större riskminskning för icke-fatala kardiovaskulära utfall jämfört med 
matchade kontroller. Patienter med typ 2 upplevde ungefär 20 % större riskreduktion 
än kontroller under samma tidsperiod. Ett paradoxalt fynd var att riskminskningen för 
fatala händelser var likartad hos patienter med typ 1 diabetes och kontroller, medan 
patienter med typ 2 uppvisade en mindre riskminskning för fatala utfall än deras 
matchade kontroller. Under de senaste 16 åren har sjukligheten och dödligheten i 
kardiovaskulära sjukdomar minskat avsevärt hos individer med diabetes.  
Patienter med typ 1 diabetes uppvisar en förhöjd risk trots optimal riskfaktorkontroll. 
Individer med typ 1 diabetes som kontrollerade alla riskfaktorer hade, jämfört med 
matchade kontroller, 82% ökad risk för akut hjärtinfarkt och 97% ökad risk för 
hjärtsvikt. Patienter med typ 1 diabetes och flera riskfaktorer uppvisar en förhöjd risk 
mellan 700-1200% för kardiovaskulär sjuklighet och död, jämfört med kontroller.  
För typ 2 diabetes minskade den förhöjda risken för komplikationer stegvis för varje 
riskfaktor som låg inom terapeutiska målområdet. För patienter med typ 2 med alla 
riskfaktorer inom målområdet så förelåg ingen nämnvärd ökad risk för död eller 
stroke men 16% lägre risk för akut hjärtinfarkt. Patienter med diabetes hade högst risk 
för hjärtsvikt, trots optimal riskfaktor kontroll. De viktigaste riskfaktorerna för 
kardiovaskulära sjuklighet och död var HbA1c, LDL kolesterol, fysisk inaktivitet och 
högt blodtryck. Lägre nivåer än dagens rekommenderade riktlinjer för HbA1c och 
systoliskt blodtryck var associerade med ännu lägre risk för komplikationer bland 
individer med typ 1 och typ 2 diabetes. 
För typ 1 diabetes var HbA1c, följt av diabetesduration och njurfunktion de viktigaste 
prediktorerna för kardiovaskulära komplikationer. 
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Slutsats 
Morbiditet och mortalitet har minskat avsevärt bland individer med diabetes. Optimal 
riskfaktorkontroll är associerad med kraftig riskreduktion för kardiovaskulära 
komplikationer och eliminerar i vissa fall den förhöjda risken. Lägre nivåer än dagens 
rekommendera riktlinjer för HbA1c och blodtryck är associerat med ännu lägre risk 
för komplikationer. Unga individer med diabetes har högst risk för komplikationer. 
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INTRODUCTION 
A brief history of diabetes mellitus 
Diabetes mellitus is a complex and heterogeneous metabolic disease that is 
characterized by persistent hyperglycemia. The disease has a long history stretching 
back into antiquity. In Ebers papyrus, a preserved medical document dating back to 
1,500 B.C, the ancient physicians of Egypt described a condition with excessive thirst 
and urination that bears resemblance to diabetes.1  
The Indian physicians, Sushruta, and his colleague Charaka (400-500 A.D.), were the 
first to identify two major categories of diabetes, later to be termed Type 1 and Type 2 
diabetes. They recognized diabetes as a syndrome with the hallmark of honey-like 
urine that affects primarily rich castes with excessive food intake. The Greek 
physician Aretaeus coined the word diabetes and wrote the first complete description 
of the disease, first century A.D. He described a disease where affected individuals 
suffer from polyuria, polydipsia, wasting syndrome and certain death. In 1775, an 
English physician named Matthew Dobson for the first time identified that glucose 
was in fact the sweet substance in the urine of patients with diabetes.2  
Over the past two centuries, our understanding of the pathogenesis and progression of 
diabetes has evolved considerably. In 1869, a medical student by the name of Paul 
Langerhans identified islands of clear cells, which was later named Langerhans islets 
that differed from the surrounding tissues in the pancreas. Not long afterwards, in 
1889, two physicians named Joseph von Mering and Oskar Minkowski experimented 
on dogs and observed that surgical removal of the pancreas resulted in diabetes. This 
laid the foundation for Frederick Banting and Charles Best, who in 1921 succeeded in 
extracting pancreatic gland serum from dogs and administered this extract to diabetic 
dogs, which resulted in lowering of blood sugar levels. Their success is considered a 
milestone in the history of medicine. In 1923, the first commercial available insulin 
product was introduced.  
During the 19th century, researchers deciphered gluconeogenesis, glycogenesis and 
glycogenolysis. Cardiovascular epidemiology began to gain momentum in the 1930s; 
several studies were set in motion to clarify the cause of cardiovascular disease 
(CVD). The most famous of these was the Framingham Heart Study, which was 
initiated in 1948. The Framingham Heart Study was the first to identify several 
cardiovascular risk factors, including hyperlipidemia, hypertension and diabetes 
mellitus. 
Recent decades have witnessed considerable advances in clinical care paralleled with 
improved management of risk factors that have transformed diabetes from a fatal 
illness to a chronic condition. Currently, diabetes is strongly associated with long-
term complications such as acute myocardial infarction, stroke, end-stage kidney 
disease, heart failure and premature death. According to recent research, patients with 
diabetes have 2 to 5 times greater risk for death and CVD, compared to the general 
population. This thesis aimed to investigate gaps in knowledge regarding the 
epidemiological aspects of death and cardiovascular events in patients with diabetes, 
with a particular focus on the relative importance of cardiovascular risk factors. The 
following subchapters will briefly describe the current understandings of type 1 
diabetes (T1DM) and type 2 diabetes (T2DM). 
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Type 1 diabetes mellitus  
T1DM is a multifactorial disease with both genetic predisposition and environmental 
factors that triggers an autoimmune response, resulting in T-cell mediated destruction 
of pancreatic β-cells and immediate need for exogenous insulin therapy. The disease 
often manifests in children or adolescents, but adults are occasionally also diagnosed 
with T1DM.  
Recent evidence indicates that an inflammatory lesion consisting of immune cells 
infiltrate the Langerhans islets several years before the onset of T1DM. The 
progressive loss of β-cells leads to overt T1DM after a latent period. Patients with 
symptomatic T1DM are believed to have lost approximately 70-90% of their total β-
cell mass.3,4  
However, not all cases of T1DM are caused by autoimmunity, a minority of the 
patients with T1DM have no detectable immune response or autoantibodies. A 
growing body of evidence suggests that theses types of T1DM have a strong genetic 
component. T1DM is the most common form of diabetes in (<15 years of age) and the 
second most common autoimmune disease in children and adolescents.3,5-7 
 
Epidemiology of T1DM 
The epidemiology of T1DM is often described as a conundrum. The incidence and 
prevalence of the disease varies between countries. Scandinavian countries display the 
highest incidence in the world in contrast to Asian countries such as China, South 
Korea and Japan were the incidence is low. The variations in incidence and 
prevalence of T1DM may be related to genetic predisposition, environmental factors 
and lifestyle factors such as childhood infections and hygiene.  
Genetic studies show that high-risk HLA-DR-DQ genotypes for T1DM, is more 
common in Scandinavian and European countries compared to Asian countries.8 The 
incidence rates for T1DM tend to be similar between boys and girls, some 
epidemiological data suggests that the peak in incidence for girls precedes that for 
boys.9,10 Studies from western countries show that incidence increases with age and 
peaks in pubertal years, according to data from Sweden the incidence peaks between 
10-14 years of age.11 The incidence rate drops after pubertal years for girls but 
remains high in men up to 35 years of age.12 
 
Pathophysiology and aetiology of β-cell autoimmunity 
T1DM is considered to be an organ-specific autoimmune disease with detectable 
inflammation surrounding the cells in the Langerhans islets, particularly β-cells. 
Histological studies reveal a higher concentration of inflammatory cells surrounding 
the β-cells. T-cell mediated destruction of the pancreatic β-cells results in insulin 
deficiency. Interaction between T-cells and B-cells lead to formation of 
autoantibodies, the autoantigens that trigger this molecular process is unknown.  
Biomarkers of autoimmunity include autoantibodies that target Langerhans islet cells, 
molecules such as insulin, glutamic acid decarboxylase (GAD65) or protein tyrosine 
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phosphatase-like molecules ZNT8, IA-2 and IA-2β. The first autoantibody that is 
usually detected in persons with T1DM is GAD65 or insulin specific autoantibodies.13  
Study of autoantibodies in T1DM will certainly lead to evolved understanding of the 
aetiology and pathogenesis of this disease. The order of appearance for these 
autoantibodies is presumably associated with age, genetic differences, environmental- 
and lifestyle factors.14 There is a stepwise relationship between increasing numbers of 
detectable autoantibodies and higher risk of developing symptomatic T1DM. 
Research indicates that persons who develop T1DM often have autoantibodies many 
years before the onset of the disease.  
Type 2 diabetes mellitus 
T2DM is a multifactorial disease that includes some of the following 
pathophysiological changes: dysregulation of protein, carbohydrate and lipid 
metabolism, as well as β-cell dysfunction, insulin resistance or a combination of 
both.15 It is now believed that impaired insulin secretion from pancreatic β-cells is the 
main cause of T2DM development, although, peripheral insulin resistance in skeletal 
muscle, liver and adipose tissue, often accompanies β-cell dysfunction. Eventually, 
the metabolism and uptake of glucose deteriorates, resulting in elevated blood sugar 
levels leading to micro- and macrovascular complications. T2DM is far more 
common than any other type of diabetes and accounts for approximately 90% of all 
cases with diabetes. 
T2DM should be regarded as a heterogeneous disease with varying clinical features 
that express themselves as different pathophysiological abnormalities, susceptibility 
of complications and response to therapeutic options. 
 
Epidemiology of type 2 diabetes mellitus 
T2DM has become a major public health concern and the International Diabetes 
Federation estimates that roughly 400 million individuals (9% of the adult population) 
worldwide suffer from T2DM, the number is expected to rise above 700 million by 
2035.16  
Asia has emerged as the area with a rapidly developing T2DM epidemic, India and 
China are the epicenters of this epidemic. In these countries, the onset of T2DM is 
characterized by lower BMI and younger age, compared to Western populations.17 
Regional differences in diabetes are thought to be due to genetic susceptibility that 
might vary between population, socioeconomic factors and poor living conditions.18,19 
The largest increases in T2DM have been observed in low- and middle-income 
countries, whereas western countries now experience a plateau in the incidence of 
T2DM. 
Recent evidence suggests that a new phenotype of T2DM is emerging, the prevalence 
of childhood and adolescent T2DM has increased dramatically in the past two 
decades.20 Studies suggest that younger individuals with T2DM have increased risk 
for cardiovascular disease and death, compared to elderly persons with T2DM. The 
disease is more prevalent in men than women.  
Evidence from twin and family studies suggest that there is a genetical basis of T2DM 
and genome-wide association studies have identified > 100 robust genetical 
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associations in large population studies, revealing the complex polygenic nature of 
T2DM.21 Genetics most likely play an important role in the development of T2DM, 
however the recent increase in prevalence and incidence of the disease cannot be 
explained by novel genetic mutations but rather lifestyle factors such as sedentary 
lifestyle and poor nutrition.22 
 
Pathogenesis of type 2 diabetes 
Effective insulin action and insulin secretion is fundamental to maintaining normal 
glucose levels, this feedback loop system does not function properly in patients with 
T2DM. The consequence of impaired insulin action in insulin-sensitive tissue and 
dysfunctional insulin secretion is increasing blood glucose levels. The cause of T2DM 
includes a combination of genetic-, epigenetic- and lifestyle factors that interacts with 
another.23 
With respect to hyperglycemia, there are other core defects implicated in the 
pathogenesis of T2DM. In general, patients with T2DM suffer from insulin resistance 
in the skeletal muscle, liver and adipose tissue, along with impaired insulin secretion 
by the pancreatic β-cells. Insulin resistance in adipose tissue leads to accelerated 
lipolysis and elevated free fatty acid levels (FFA), research indicates that increased 
FFA levels worsens insulin resistance in muscle, liver and β-cells. It is hypothesized 
that elevated FFA levels contributes greatly to central β-cell dysfunction.  
Research shows that β-cells develop a resistance to glucagon-like peptide 1 (GLP-1) 
in T2DM, this is believed to accelerate β-cell dysfunction even further. The 
reabsorption of glucose in the kidneys by the sodium/glucose co-transporter 2 (SGLT-
2) leads to increased blood glucose levels and exacerbates the underlying insulin 
resistance. Moreover, individuals with type 2 diabetes often develop resistance to 
appetite-regulating neurohormones such as insulin, GLP-1, amylin and peptide YY, 
leading to weight gain and progression of the disease. 
In 1990, researchers reported that a cytokine called tumor necrosis factor-α, which is 
created by adipocytes and overproduced in obesity, could attenuate metabolism 
locally and systematically.24,25 Consequently, other scientists started examining the 
relationship between inflammation and metabolic diseases such as T2DM, metabolic 
syndrome and obesity. Dramatics understanding of the link between inflammation and 
T2DM followed and numerous cytokines and adipokines were discovered in the 
following years.  
T2DM is associated with obesity and insulin resistance, two conditions that are linked 
to systemic inflammation. Histological examination of adipose tissue reveals 
macrophage infiltration around adipocytes and increased secretion of pro-
inflammatory cytokines that contribute to chronic systemic inflammation in T2DM. 
Still, the exact physiological event that resulted in activation of the immune system in 
obesity remains incompletely understood. 
 
Blood glucose and organ damage 
Dysglycemia, the hallmark of diabetes mellitus is presumably the most important 
factor in this disease and causes organ damage through several proposed 
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pathways.26,27 This leads to micro- and macrovascular complications through the 
activation of several known pathways, although the exact molecular mechanisms are 
not fully understood. Vascular and interstitiell organ damage is presumably caused 
from increased formation of advanced glycation end products (AGEs), increased 
expression of AGE receptors, the polyol pathway, activation of PKC isoforms, 
increased hexosamine fluctuations and higher intracellular levels of reactive oxygen 
species (ROS).28,29 
 
Diabetes-related complications 
Diabetes-related complications are divided into acute and chronic conditions. Acute 
complications include the following; diabetes ketoacidosis, hyperglycemic 
hyperosmolar state, hypoglycemia and diabetes coma. Chronic complications are 
divided into micro- and macrovascular complications that represent a wide spectrum 
of different disorder. The macrovascular complications include acute myocardial 
infarction (AMI), coronary heart disease (CHD), cerebrovascular disease and 
peripheral arterial disease (PAD), whereas microvascular complications include 
nephropathy, retinopathy, neuropathy and autonomic neuropathic disease. 
Patients with T1DM predominantly suffer from CHD, which reflects the accelerated 
atherosclerotic process in the coronary vasculature of these patients.30,31 
Epidemiological studies suggest that all cardiovascular complications are declining in 
patients with diabetes, perhaps with the exception of heart failure. Recent randomized 
trials and epidemiological observation studies suggest that heart failure is an emerging 
and probably forgotten diabetes-related complication.32  
In order to decrease the risk for micro- and macrovascular complications, a 
multifaceted management strategy is necessary. This includes intensive insulin 
therapy, nutritional awareness, healthy diet, and regular physical exercise. Lifestyle 
changes and management of cardiovascular risk factors such as hypertension, 
dyslipidemia, hyperglycemia and overweight is fundamental to diabetes care. A 
favorable risk factor profile reduces the risk for morbidity and mortality among 
individuals with diabetes. 
 
The link between diabetes and cardiovascular disease 
Cardiovascular disease was uncommon during the beginning of the 19th century, 
however as some parts of the world underwent industrialization and subsequent 
lifestyle changes, the prevalence of these diseases increased. During the 1970’s the 
prevalence of cardiovascular disease culminated in the industrialized parts of the 
world and the 20th century witnessed a rapid increase particularly of fatal CHD. 
Today, cardiovascular disease is the leading cause of death among individuals with 
diabetes.  
In 1948, Ernest Millard and Howard Root observed that persons with diabetes and 
poor glucose control have more severe retinopathy than other patients. Molecular 
research and epidemiological studies in diabetes had implicated hyperglycemia in the 
pathogenesis of long-term complications, but previous clinical trials had not 
demonstrated a consistent or convincing beneficial effect of intensive insulin therapy. 
In 1993, the DCCT was the first study to demonstrate that normalization of glycemic 
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control by means of intensive insulin therapy reduced the risk of neuropathy, 
nephropathy and retinopathy by 35% to 70% in patients with insulin-dependent 
diabetes mellitus (IDDM). 
In 1974, the Framingham heart study established diabetes mellitus as a risk factors for 
cardiovascular complications, their study demonstrated that men and women with 
diabetes had two and five times elevated risk of heart failure, as compared with non-
diabetic individuals. In 1979, the Framingham study demonstrated that patients with 
diabetes had a twofold to threefold increased risk of intermittent claudication, 
congestive heart failure and coronary heart disease.33 Since the publication of these 
findings, numerous studies were initiated in order to study the epidemiology of 
diabetes and CVD. Currently, there is an abundance of epidemiological studies that 
demonstrate an elevated relative risk for CVD among patients with diabetes.34-37 The 
highest relative risk has been shown for CHD and heart failure,38 while some 
epidemiological reports suggest that diabetes may be protective for some vascular 
conditions such as hemorrhagic stroke or aortic dissection.39 
Coronary mortality has declined substantially in patients with diabetes, both in 
absolute and relative risks. Between 1990 and 2010, incidence rate of acute 
myocardial infarction in the US declined from 141 to 46 per 10,000 (68%), while for 
stroke it declined from 112 to 53 (53%).36 
Heart failure has often been neglected as a cardiovascular complication of diabetes, 
but is now increasingly being recognized. Diabetes mellitus contributes to the 
development of heart failure through several proposed pathways, beyond the obvious 
risk of developing ischemic heart disease and hypertension, which both cause heart 
failure. It is believed that hyperglycemia directly affects the myocardium in a negative 
way. Elevated blood sugar levels could contribute to non-ischemic fibrotic 
remodeling of the myocardium, which leads to heart failure. The EMPA-REG study 
reported that empagliflozin, a sodium-glucose co-transporter-2 inhibitor (SGLT-2) – 
that increases the excretion of glucose and sodium in the kidneys – brought about a 
34% reduction in the risk of heart failure in patients with T2DM.32 
  
Multifactorial risk factor intervention 
Patients with diabetes have an increased risk for death and cardiovascular 
complications, as compared with diabetes free individuals. There are multiple 
modifiable risk factors for chronic complications in patients with diabetes. For 
instance hypertension, hyperlipidemia, hyperglycemia, smoking and arguably even 
albuminuria are modifiable risk factors.40-42 Prospective data on the benefits of 
multifactorial risk factor intervention in patients with diabetes is sparse. Current 
guidelines and estimations of treatment effects are based on studies examining one or 
two risk factors, not the whole range of risk factors. 
Randomized clinical trials have extensively evaluated the effect of treating individual 
risk factors in studies such as The United Kingdom Prospective Diabetes Study 
(UKPDS), Collaborative Atorvastatin Diabetes Study (CARDS), the Diabetes Control 
and Complications Trial (DCCT) etc.43-47  
Persons with diabetes are reported to on average have a 2 to 5-fold increased risk of 
cardiovascular disease (CVD) and death compared to the general population. Even 
with a glycated hemoglobin level below the target level of 6.9% (52 mmol/mol), the 
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risk of cardiovascular disease and mortality is still on average twice that of the 
general population.27,48 Based on the results from clinical trials, the American 
Diabetes Association and other national guideline committees recommend a 
multifactorial treatment approach. 
However, few studies have evaluated the effect of multifactorial risk factor control 
aimed at several modifiable risk factors in patients with diabetes.42,49 Moreover, the 
preventive strategies for cardiovascular disease in persons with T1DM is sometimes 
extrapolated from clinical trials based on persons with T2DM. These research 
questions are therefore even less studied in T1DM. 
The Steno-2 study was one of the first clinical trials to evaluate the effect of 
multifactorial risk factor intervention among patients with T2DM. This unique 
clinical trial evaluated the cumulative effect of behavior modification and 
polypharmacological therapy aimed at several modifiable risk factors. The study 
revealed that multiple risk factor intervention reduced the risk of cardiovascular 
events among patients with T2DM and microalbuminuria. The Steno-2 study reported 
a 20% relative risk reduction of cardiovascular events among those with multifactorial 
risk factor intervention. This magnitude of effect is higher than what is usually 
observed in studies that apply single-factor interventions.40,50,51 
Patients (in Steno-2) receiving intensive multiple risk factor intervention had a 
significantly greater reduction of systolic and diastolic blood pressure, serum 
cholesterol, triglyceride levels and urinary albumin excretion. This presumably 
explains the reduction in risk of cardiovascular events observed among these 
individuals.40 The Steno-2 study also reported a relative risk reduction for CV death 
by 46% (hazard ratio, 0.54; 95% CI, 0.32 to 0.89).40 The Steno-2 studies were not 
designed to identify which elements of intensive diabetes therapy that contributed 
most to the reduction in cardiovascular risk. 
Nevertheless, the Steno-2 Study only included 160 study participants and the study 
design precludes the possibility to link observed benefits to achievement of specific 
treatment targets. Hower et al, observed benefits of tighter cholesterol and blood 
pressure target on carotid atherosclerosis in the SANDS (stop Atherosclerosis in 
Native Diabetics study) trial.52 The ACCORD trial showed that aggressive treatment 
of hyperglycemia among patients with T2DM resulted in increased risk for mortality 
but not cardiovascular events.53 The INVEST study suggested small but significant 
increases in mortality among patients with diabetes and CHD who achieved systolic 
blood pressure <130 mm hg compared with less stringent control.54  
The BARI 2D study was initiated to compensate for shortcomings of the Steno-2 
study.49 The BARI 2D study included patients with T2DM with angiographically 
documented stable CHD. This study evaluated the effect of multiple risk factor 
control during 13 years of follow-up. BARI 2D evaluated 6 risk factors but observed 
that there is a plateau of benefit at 5 risk factors under control with only a small 
increase in risk among those who had 6 risk factors under control. 
Thus, the evidence base for multifactorial risk factor control is sparse. We therefore 
aimed to examine the relative risk of multifactorial risk factor control in a nationwide 
cohort of patients with diabetes, compared to matched controls from the general 
population.  
Epidemiological aspects of cardiovascular morbidity and mortality among individuals with diabetes 
 
 20
AIMS 
The aim of this thesis was to study the long-term trends of mortality and 
morbidity among patients with diabetes, and the relative importance of 
cardiovascular risk factors. The specific aims of the individual studies are listed 
below. 
 
I. Investigate long-term trends in incidence and risk of all-cause mortality 
and cardiovascular outcomes among patients with diabetes, compared 
to age-, sex- and county matched controls from the general population.  
 
 
II. To analyze if the excess risk of death and cardiovascular outcomes in 
persons with T1DM can be eliminated by means of optimal risk factor 
control. To investigate the benefit of maintaining risk factors within 
therapeutic guideline target levels. 
 
III. To analyze which risk factors that appears to be the most important in 
primary prevention of persons with T2DM. Also, we investigated the 
benefit of multiple risk factor control as well as optimal levels for three 
selected risk factor in persons with T2DM. Similar to the second paper, 
we explored the possibilities to eliminate excess risk by means of 
optimal risk factor control in T2DM. 
 
IV. To examine if age of onset of T1DM is an important risk stratifier and 
how this factor relates to excess risk for mortality and cardiovascular 
events. To assess differences in risk between women and men with 
T1DM, according to age at onset of disease. 
 
V. To examine which risk factors that appears to be most important for 
predicting death and cardiovascular events among persons with T1DM. 
Similar to the third paper, we examined the optimal level for three 
selected risk factors. 
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PATIENTS AND METHODS 
Study registries 
This thesis includes information from several national health registries. The main data 
source is the National Diabetes Register (NDR). Due to the unique Swedish personal 
identification number we have the possibility to link data from the following national 
health registries: the Swedish Inpatient and Outpatient Registry (IPR and OPR), 
Cause of Death Registry and the Longitudinal Integration Database for Health 
Insurance and Labour Market Studies (LISA).  
The NDR was initiated in 1996 and includes information on clinical characteristics, 
risk factors, laboratory analyses, complications of diabetes, and medications for 
patients 18 years of age or older. The registry includes more than 500,000 individuals 
with diabetes. Each patient provides informed consent for inclusion in the register, 
and virtually all patients in Sweden with diabetes are included. More than 95% of all 
individuals with T1DM and 90% of individuals with T2DM in Sweden are included 
in the NDR.  
 
The Cause of Death Register provides information for date and cause of death, the 
registry had complete coverage since 1961. The IPR and OPR include all inpatient- 
and outpatient diagnoses with complete coverage since 1987. The LISA database 
provides information about socioeconomic status (education, income, occupation and 
ethnicity) with complete coverage since 1990.  
 
We included patients with diabetes that were ≥18 years or older and registered in the 
NDR between January 1, 1998 – December 31, 2012. Approximately 430,000 patients 
with T2DM and 37,000 patients with T1DM were included in the analyses of this 
thesis. All studies were approved by the Regional Ethics Review Board of 
Gothenburg, Sweden (diary numbers: epn 563-12).  
Figure 1. Schematic figure of all health registries that were included
National Diabetes Register Data available for >500,000 
individuals with diabetes
Personal
iden ?ti cation 
number
LISA Inpatient register
Outpatient register
Cause of death 
register
Discharge diagnosis
Socioeconomic variables
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Outcomes 
Information on cardiovascular events and deaths were retrieved by linking data to the 
Swedish Inpatient Register and the Cause of Death register, using the 9th and 10th 
revision for International classification of disease (ICD). We assess the following 
ICD-codes: coronary heart disease (410-414 [ICD-9], I20-I25 [ICD-10], of which 410 
and I21 coded acute myocardial infarction); stroke (431-434, 436 [ICD-9], I61-I64 
[ICD-10]) and hospitalization for heart failure (428 [ICD-9], I50 [ICD-10]).  
In addition to the abovementioned outcomes, we include other outcomes for mainly 
two reasons, the outcome is either specified as an exclusion criteria or adjusted for as 
a comorbidity, we included the following outcomes: atrial fibrillation (427D [ICD-9], 
I48 [ICD-10]), end-stage kidney disease (V42A, V45B, V56A, V56W [ICD-9], Z940, 
Z491, Z492, Z992 [ICD-10]) and amputation (NHQ09, NHQ11, NHQ12, NHQ13, 
NHQ14, NHQ16, NHQ17, NHQ99, NGQ09, NGQ19, NGQ99, NFQ19, NFQ99 
[ICD-10]).  
We analyzed both fatal and non-fatal outcomes in each study, for fatal outcomes we 
included up to 5 contributory causes for fatal outcomes and up to 7 contributory 
causes for non-fatal outcomes.  The sensitivity and specificity for these diagnoses 
have been validated previously.55  
 
Definition of type 1 diabetes and type 2 diabetes 
The studies in this thesis are based on the main two forms of diabetes mellitus, 
namely T1DM and T2DM. T1DM was defined using the epidemiologic definition: 
treatment with insulin and diagnosis at ≤30 years of age. T2DM was also defined 
using the epidemiologic definition: treatment with diet with or without the use of oral 
antihyperglycemic agents or treatment with insulin with or without the use of oral 
antihyperglycemic agents; the latter category only applied to patients who were 40 
years of age or older at the time of diabetes diagnosis.  
The concordance between the epidemiological definitions and clinicians classification 
have been scrutinized previously, the concordance among patients diagnosed with 
diabetes before 2004 and 2009 was 96% and 95%, respectively. 
 
Statistical methods 
This thesis includes several statistical approaches that address different research 
questions. A brief discussion of the statistical methods follows. 
In Study I, we used a Cox regression model that includes the following covariates: 
age, gender, a discrete variable termed type (i.e. either patient with diabetes or 
matched control) and a continuous variable termed time-period. Also, we included 
two interactions terms in these Cox models. The first interaction variable was between 
type and time-period (type*time-period), which allows us to evaluate the changes in 
relative risk between patients with diabetes and matched controls. The second 
interaction includes type with age and gender, since we believe that these variables 
should exert separate effects on the Cox model for patients with diabetes and matched 
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controls. In addition, we assessed age and sex standardized incidence rates for 
patients with diabetes and matched controls. 
The variable time-period consisted of two consecutive calendar years. Therefore we 
exponentiated the interaction variable type*time-period by 5 to estimate a ten-year 
relative rate reduction, we applied the same method for confidence intervals. 
 
In Study II, we constructed 6 groups according to number of risk factors that were 
within therapeutic guideline target levels (0 to 5 risk factors). These risk factors 
included glycated hemoglobin, systolic and diastolic blood pressure, hyperlipidemia, 
smoking status and renal function. Thereafter, we calculate crude incidence rates as 
number of events per 10,000 persons-years of observation for death and 
cardiovascular events according to number of risk factors within target levels in 
patients with T1DM. Also, we used Cox regression to estimate the risk of each 
outcome among persons with T1DM, compared to matched controls. These regression 
models were adjusted for income, education, marital status, immigrant status, age, 
duration of diabetes and status at baseline with regard to a history of conditions. The 
models were stratified on sex to allow for different underlying baseline hazards for 
men and women. 
 
In Study III, we investigated three separate research questions. We constructed a Cox 
model to estimate the excess risk in people with T2DM in relation to the number of 
risk factors within target range. As for T1DM, number of factors within target ranged 
from 0 to 5. These models were stratified on sex and we used age as the time-scale. 
Socioeconomic variables such as income, education, marital status and country of 
origin were also included in these models. These regression models did not include 
physical activity, body mass index and the use of statins or antihypertensive 
medications since the data are not available for matched controls. 
In the first ancillary analysis, we evaluated the relative importance of multiple risk 
factors. There are different statistical approaches to estimate the relative importance 
for covariates in a regression model. We used statistical methods that were available 
for Cox regression (explained relative risk [R2] and the Chi-square method), A strong 
risk factor will contribute more to the predictive ability, compared with a less strong 
predictor. 
In these Cox models, the variable age was used as the time-scale. When age was 
included as a covariate in the Cox model it outperformed all other predictors by far 
(displaying the largest R2). The second application available to assess relative 
importance of risk factors in the cox model is the explained log-likelihood of each 
predictor. This statistical model estimates the partial effect of each risk factor by 
quantifying the proportion of explainable log-likelihood explained by each risk factor. 
In the third ancillary analyses, we used a Cox model with restricted cubic splines for 
continuous variables to assess the hazard function for different values for risk factor. 
We set the guideline target levels as reference values for each risk factor. The risk 
factors that were studied were the following: glycated hemoglobin, systolic blood 
pressure and low-density lipoprotein cholesterol. For glycated hemoglobin we used 53 
mmol/mol (7.0%), for systolic blood pressure 140 mmHg and for low-density 
lipoprotein cholesterol 2.5 mmol/L. 
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In Study IV, we used Cox regression to analyze the association between age at 
diagnosis of T1DM and risk of outcomes. The regression models included age as the 
time-scale, gender, socioeconomic variables, duration of diabetes and previous 
histories of cardiovascular events. Persons with T1DM were categorized into five 
groups according to age at diagnosis. 
 
In Study V, we used Cox regression and machine-learning models to assess the 
relative importance of risk factors among persons with T1DM. In addition, we set out 
to investigate the association of different levels for the selected risk factors glycated 
hemoglobin, systolic blood pressure and low-density lipoprotein cholesterol. The cox 
regression models that we used in this study are virtually identical to the cox models 
in Study III.  
Machine learning models are robust statistical tools to assess relative importance of 
risk factors, particularly when the number of features (predictors) is large. We 
constructed machine learning models referred to as random survival forest and 
gradient boosting, which are supervised ensemble techniques that deploy decision 
trees to predict the response variable. The algorithm includes evaluations of variable 
importance at each split (node) in the tree. The predictive value of each risk factor is 
averaged from all trees to estimate the relative importance of each predictor. A 
significant advantage of machine learning is the inherent capability to detect and 
handle higher-order interactions and non-linearity in the data. 
 
Imputation of missing data 
Epidemiological studies often involves handling of missing data, researchers can 
chose to study complete cases only or use imputation techniques to maximize power 
and avoid selection bias. We used an imputation method called multivariate 
imputation by chained equations (MICE) to impute datasets with complete data. First, 
MICE impute each missing variable with mean values. The model creates linear and 
logistic regression for all variables to predict coefficients for missing values, using the 
complete dataset. We compared the result from imputation with different imputation 
methods and mean values for risk factors, before and after imputations. 
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RESULTS 
Study I: Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes 
Reports show that incidence rates of death and cardiovascular events have 
declined among persons with and without diabetes. Our primary objective was 
to compare the change in relative risk of outcomes over time, between patients  
 
 
 
with diabetes and matched controls. The analysis revealed substantial decreases 
in relative risk for persons with and without diabetes. Patients with diabetes 
had a significantly greater relative risk reduction for non-fatal cardiovascular 
events. We did not observe this for fatal outcomes, patients with T1DM had 
comparable relative risk reduction as matched controls.  
Patients with T2DM had more than 20% greater relative risk reduction for non-
fatal cardiovascular outcomes, compared to matched controls. For patients with 
T2DM, we report that the general population experienced almost 10% greater 
risk reduction than patients with diabetes. This paradoxical finding is to our 
knowledge a previously unknown feature in cardiovascular epidemiology for 
patients with T2DM.
Figure 2. Cardiovascular outcomes and death among patients with type 2 diabetes and matched 
controls. Standardized incidence rates per 10,000 person-years. 
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Mortality among patients with T2DM changes by -69.6 deaths (95% CI, -95.9 
to -43.2) per 10,000 person-years. In matched controls, mortality was -134.7 
deaths (95% CI, -145.2 to -124.1) per 10,000 person-years. Patients with 
T2DM, continue to display an excess risk for CVD and death, compared to 
matched controls. Hospitalization for cardiovascular disease experienced the 
greatest relative risk reduction out of all outcomes in patients with T2DM. 
Death among patients with T1DM was -31.4 deaths (95% CI, -56.1 to -6.7) per 
10,000 person-years. Hospitalization for CHD experienced the greatest 
absolute decline out of all outcomes in patients with T1DM, -69.6 (95% CI, -
97.7 to -41.5) per 10,000 person-years.  
A combination of standardized incidence rates and cox models offers a unique 
opportunity to assess this research question accurately. It is sometimes 
challenging to determine the absolute change in incidence rates for 
cardiovascular events and death in patients with diabetes and matched controls. 
We used cox models to estimate the relative risk reduction in all study 
participants. Moreover, the cox model allows us to compare the change in 
relative risk over time, between patients with diabetes and matched controls.  
Figure 3. Cardiovascular outcomes in patients with type 1 diabetes and matched controls were 
matched for age, sex and county. Standardized incidence rates per 10,000 person-years. 
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significantly greater than matched controls (HR, 0.97; 95% CI, 0.80 to 1.18). In 
contrast, non-fatal CHD declined by 39% more in patients with T1DM than matched 
controls (HR 1.39; 95%, 1.22 to 1.76). Patients with T2DM experienced a 27% 
greater relative risk reduction for non-fatal CVD, compared to matched controls 
(hazard ratio 1.27; 95%, 1.22 to 1.32). 
 
Study II: Range of risk factor levels/controls, mortality and cardiovascular outcomes in 
type 1 diabetes     
Observational studies have recently established that persons with T1DM with 
glycated hemoglobin levels below therapeutic target levels of 6.9% (52 mmol/mol), 
still have increased risk for cardiovascular events and death, compared to matched 
controls. 
We therefore decided to study the possibilities of reducing or eliminating excess risk 
for CVD and mortality in patients with T1DM, by means of multifactorial risk factor 
control.  
This cohort comprised of 33,333 persons with T1DM and 166,529 matched controls. 
Patients were categorized into 6 groups, based on number of risk factors at target 
level, ranging from 0–5 risk factors. We investigated the following risk factors: 
glycated hemoglobin, systolic- and diastolic blood pressure, low-density lipoprotein 
cholesterol, smoking and renal function (i.e. micro- and macroalbuminuria).  
 
Figure 4. Adjusted hazard ratio for death and myocardial infarction according to number of risk factors 
at target in patients with type 1 diabetes, compared to matched controls. 
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Incidence rate for all-cause mortality in persons with T1DM with all risk factors 
within therapeutic target level was 1.58 (95% CI, 0.95 to 2.21) death per 1000 person-
years, the adjusted hazard ratio for mortality in this patient group was 1.31 (95% CI, 
0.93 to 1.85). The hazard ratio for patients with diabetes and none of the 5 risk factors 
at target level was 7.33 (95% CI, 5.08 to 10.57). 
Persons with T1DM, with all risk factors within therapeutic target levels continued to 
display an elevated risk for acute myocardial infarction and hospitalization for heart 
failure, 1.82 HR (95% CI, 1.15 to 2.88) and 1.97 HR (95% CI, 1.04 to 3.73) 
respectively. Patients with T1DM appear to have greatest risk for hospitalization for 
heart failure, irrespective of the number of risk factors at target. We performed a 
subanalysis and studied the risk of mortality in patients with T1DM, for men and 
women. The adjusted hazard ratios were very similar between both genders. Our 
analysis of multifactorial risk factor control in patients with T1DM revealed a 
monotone relationship between increasing number of risk factors and increasing risk 
for outcomes. 
 
Study III: Risk factors, mortality, and cardiovascular outcomes in patients with type 2 
diabetes 
The importance of multifactorial risk factor intervention in patients with T2DM has 
been studied sparsely. The Steno-2 research group analyzed cumulative risk reduction 
from multifactorial risk factor intervention, compared to standard care for selected 
cardiovascular risk factors. Their findings suggest that multifactorial risk factor 
Figure 5. Adjusted hazard ratios for hospitalization for heart failure and stroke according to number of risk factors 
at target in patients with type 1 diabetes, compared to matched controls 
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intervention leads to risk reduction for all-cause mortality, micro- and macrovascular 
complications and amelioration of several cardiovascular risk factors.40,42,50,51  
A drawback of these studies was the small study cohort that included less than 400 
study participants. The Steno-2 studies investigated the effect of multifactorial risk 
factor intervention against all risk factors concurrently, compared to standard care for 
all risk factors. Our study used a nationwide cohort of patients with T2DM to study 
the risk of death and cardiovascular outcomes for each risk factor within therapeutic 
target level. We studied the following risk factors: glycated hemoglobin, blood 
pressure, low-density lipoprotein cholesterol, smoking status and renal function (i.e. 
micro- and macroalbuminuria).  
After applying exclusion criteria, the analyses included 271,174 patients with T2DM 
and 1,355,870 matched controls.  
Numbers of risk factors at target 
Our findings show that persons with T2DM and all risk factors at target had 
marginally increased risk for death and stroke, while risk for acute myocardial 
infarction was lower than matched controls. In patients with T2DM and all risk 
factors at target, the risk for mortality was HR 1.06 (95% CI, 1.00 to 1.12) and for 
acute myocardial infarction HR 0.84 (95% CI, 0.75 to 0.93). Patient with T2DM 
seems to have highest risk for hospitalization of heart failure, even with all risk 
factors at target, patients with diabetes have 45% (HR 1.45 (95% CI, 1.34 to 1.57) 
excess risk for heart failure compared to matched controls.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Adjusted hazard ratios for death and myocardial infarction according to age at baseline 
and number of risk factors within target level in patients with type 2 diabetes, compared to matched 
controls 
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Our analyses demonstrate a monotone relationship between increasing number of risk 
factors within therapeutic target level and lower risk for death and cardiovascular 
outcomes. Patients with T2DM with none of the 5 risk factors within target level have 
about 500–1800% excess risk for death and cardiovascular events.  In addition, we 
noticed a monotone relationship between younger age at baseline in patients with 
T2DM and increased risk for outcomes.  
 
 
Adolescents with T2DM (<55 years of age) had highest risk for death and 
cardiovascular, out of all age groups, irrespective of the number of risk factors at 
target. We did not observe excess risk for outcomes in elderly individuals with T2DM 
(≥80 years of age or older), hazard ratios for this patient group was at most, 
marginally increased.  
Strength of association for risk factors 
In an ancillary analysis, we studied the strength of association of every risk factor to 
identify the strongest predictor for cardiovascular disease and death. We used two 
specific applications for the Cox model to estimate the relative importance of each 
risk factor. Our analyses reveals that low physical activity, glycated hemoglobin, 
systolic blood pressure, low-density lipoprotein cholesterol and smoking are the most 
important predictors for cardiovascular disease and death in patients with T2DM.  
We performed these analyses in two different cohorts for patients with T2DM, one 
cohort with and without previous CVD at baseline. For premature death, smoking, 
low physical activity and marital status were the strongest predictors, these results 
were evident in both cohorts.  
Figure 7. Adjusted hazard ratios for stroke and heart failure according to age at baseline and number of 
risk factors within target level in patients with type 2 diabetes, compared to matched controls 
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For acute myocardial infarction, glycated hemoglobin, systolic blood pressure and 
low-density lipoprotein cholesterol were the strongest predictors. The strength of 
association analysis showed virtually similar results for myocardial infarction and 
stroke, with the exception of duration of diabetes and low physical activity that were 
more important predictors for stroke than myocardial infarction. 
 
 
For heart failure, there was a clear difference between the cohorts with and without 
comorbidities at baseline. In persons with T2DM and history of conditions at 
baseline, the strongest predictor for hospitalization of heart failure was atrial 
fibrillation. In a cohort without comorbidities at baseline, the strongest risk factors 
proved to be body mass index, glycated hemoglobin and low physical activity. 
Figure 8. Strength of association of risk factors for death and stroke among patients with type 2 diabetes 
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Optimal levels for selected risk factors 
In the second ancillary analysis, we constructed cox models with restricted cubic 
splines for continuous covariates. Our primary objective was to analyze risk for death 
and cardiovascular events according to various levels of three selected risk factors.  
Figure 9. Strength of association of risk factors for myocardial infarction and heart failure among patients 
with type 2 diabetes
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We investigated the following risk factors: glycated hemoglobin, systolic blood 
pressure and low-density lipoprotein cholesterol. According to our models, these three 
risk factors display non-linear association with mortality and heart failure, whereas 
the risk of myocardial infarction and stroke displays a fairly linear relationship with 
these risk factors. Increasing levels of glycated hemoglobin seemed to be associated 
with most prominent increase in risk for mortality, stroke and heart failure. 
Increasing values for these three risk factors displayed almost a linear relationship 
with AMI. Moreover, lower levels than recommended target levels were associated 
with reduced risk for myocardial infarction. For stroke and AMI we notice a plateau 
after a certain level for glycated hemoglobin, whereas systolic blood pressure and 
low-density lipoprotein cholesterol displays a clear linear relationship for increasing 
levels. 
For stroke, we observed that lower levels of glycated hemoglobin and systolic blood 
pressure were associated with significant risk reduction in patients with T2DM. For 
heart failure, increasing levels of glycated hemoglobin displayed a clear association 
with increasing risk. A clear non-linear association is only seen for systolic blood 
pressure in all-cause mortality and heart failure.  
 
Study IV: Excess mortality and cardiovascular disease in young adults with type 1 diabetes 
in relation to age at onset: a nationwide register-based cohort study 
Age at onset of diabetes is presumably an important factor for death and CVD in 
T1DM, but this variable is not considered in current risk mitigation strategies. 
Therefore, we set out to determine to contribution of age at onset as a risk factor for 
cardiovascular events and death in individuals with T1DM.  
We performed all analyses for patients with T1DM and compared them with matched 
controls. Our analyses shows that persons with T1DM with disease onset before 10 
Figure 12. Expected median survival for age at onset of type 1 diabetes compared to 
matched controls 
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years of age had 30-times increased risk of AMI, women with T1DM had 60-times 
increased risk for CHD and 90-times higher risk for myocardial infarction. Onset of 
T1DM at 25–30 years of age was associated in approximately 5-times lower risk of 
death and CVD, compared to the age group 0-10 years. 
Moreover, we constructed cox models to assess conditional mean survival, which 
showed that patients with T1DM lost several life-years from their disease. Patients 
with T1DM that were diagnosed before 10 years of age had 16.0 life-years lost due to 
their disease, life-expectancy seems to be shorter in women with T1DM. The 
conditional mean survival increases in patients with higher age at onset of diabetes.  
The adjusted hazard ratio for mortality was highest in the youngest age group and the 
risk decreased in a stepwise fashion with increasing age. Comparable results were 
seen for cardiovascular mortality. Patients with onset of disease before 10 years of 
age have 30-times higher risk for CHD (HR 30.50 (95% CI, 19.98 to 46.57), 
corresponding hazard ratios for heart failure is HR 12.90 (95% CI, 7.39 to 22.51).  
We observed significant differences in risk for cardiovascular outcomes and death 
between women and men. Being a woman with T1DM seems to be associated with 
higher risk for cardiovascular events and death, compared with men. 
 
Women with T1DM had particularly high risk for CHD and AMI, hazard ratio 58.73 
(95% CI, 28.86 to 119.55) and hazard ratio 92.07 (95% CI, 32.72 to 253.47), 
respectively.  
Men with T1DM had greater risk for developing heart failure, compared to women. 
Also, we studied the causes of death in age groups and noticed that circulatory- and 
endocrine causes of death are the most common causes of death among persons with 
T1DM, and the prevalence of these outcomes increases in younger age groups. 
Figure 13. Adjusted hazard ratios for age at onset of type 1 diabetes for mortality and other cardiovascular outcomes 
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Study V: Relative prognostic importance and optimal levels of risk factors for mortality 
and cardiovascular outcomes in type 1 diabetes  
We investigated the strength of association for risk factors and varying levels of 
glycated hemoglobin, systolic blood pressure and low-density lipoprotein cholesterol 
for cardiovascular events and death, in patients with T1DM.  
We used two developed applications for the cox proportional hazards model with two 
separate machine learning models, to accurately assess the relative importance of risk 
factors among patients with T1DM. The cohort that we studied included 32,611 
patients with T1DM. 
The results show that age was the strongest predictor for death and CV outcomes. 
Risk factors that capture some element of time (e.g. age, age at onset of diabetes or 
duration of diabetes) all demonstrated elevated strength of association. Glycated 
hemoglobin and albuminuria were the two risk factors that had highest relative 
importance measure, second to age. Income and systolic blood pressure were also 
strong predictors for mortality. The strongest predictors for myocardial infarction 
were duration of diabetes, LDL-C and glycated hemoglobin.  
 
 
Our machine learning models suggest that duration of diabetes, albuminuria and 
systolic blood pressure interact with glycated hemoglobin. For each mmol/l higher 
LDL-C, the risk for myocardial infarction increased with 47% (HR 1.47; 95% CI, 
1.39 to 1.55). We observed rather similar findings for stroke and myocardial 
infarction, with the exception of systolic blood pressure and low physical activity 
level that were more associated with stroke. Each unit increase in systolic blood 
pressure was associated with 1.5% increase in hazard ratio (HR 1.015; 95% CI, 1.011 
to 1.02), equating to 16% (12–20%) risk difference for each 10-mmHg increase. 
 
 
 
Figure 14. Strength of association of risk factors for mortality and myocardial infarction in patients with 
type 1 diabetes according to machine learning models random forest and gradient boosting 
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The strength of association for risk factors is quite similar between the cox models 
and machine learning analyses. Bear in mind, that the machine learning analyses takes 
higher-dimensional interactions into account, meaning that other risk factors could 
interact and modify the strength of association for other risk factors.  
 
According to our models, risk factors that denote some kind of exposure time, e.g. 
age, age at onset of diabetes and duration of diabetes, all interact and modify the 
strength of association for risk factors. 
 
 
 
Figure 15. Strength of association of risk factors for stroke and heart failure in patients with type 1 diabetes 
according to machine learning models random forest and gradient boosting. 
Figure 16. Strength of association of risk factors for mortality and acute myocardial infarction in patients 
with type 1 diabetes according to the explained relative risk model (R2) and the explained log-likelihood 
model 
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In a complementary analysis, we excluded age and duration of diabetes as predictors 
from the machine learning models. This gives us the opportunity to compare strength 
of association for risk factors in a model with and without these strong interacting 
predictors.  
The complementary analysis showed that systolic blood pressure and eGFR increased 
significantly in strength of association when age and duration of diabetes are omitted 
from the machine learning analyses.  
 
Figure 17. Strength of association of risk factors for stroke and heart failure in patients with type 1 diabetes 
according to the explained relative risk model (R2) and explained log-likelihood model. 
Figure 18. Strength of association of risk factors, according to gradient boosting without age and duration 
of diabetes for outcomes in patients with type 1 diabetes 
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The importance of glycated hemoglobin decreases for all outcomes, in machine 
learning models that does not include age and duration of diabetes, see Figure 21 for 
more details. The effect of glycated hemoglobin is maybe partly mediated through the 
predictor’s duration of diabetes and age.  
In a final analysis on strength of association for risk factors, we averaged the relative 
contribution of each risk factor to their respective model, and calculated an average 
from all four statistical models and for each outcome. The averaged relative 
contribution of each risk factor for each outcome was termed relative importance, see 
figure 18 for more details.  It is difficult to compare results between the cox models 
and machine learning analyses. 
 
Figure 19. The relative importance of risk factors for cardiovascular outcomes and death among patients 
with type 1 diabetes. This figure is based on the relative contribution from all statistical models. 
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Analysis of optimal levels for risk factors in patients with T1DM 
Similar to study III, we analyzed the associated risk for varying levels of the selected 
risk factors, glycated hemoglobin, systolic blood pressure and low-density lipoprotein 
cholesterol. Lower levels for systolic blood pressure and low-density lipoprotein 
cholesterol below current guideline levels were associated with lower risk for 
cardiovascular events and death.  
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Lower levels of glycated hemoglobin than current target levels is associated with 
lower risk for myocardial infarction, stroke and heart failure, however, glycated 
hemoglobin displayed a U-shaped relationship for mortality. We observed a linear 
relationship between these risk factors and myocardial infarction.  
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DISCUSSION 
Two decades of continual decline in cardiovascular events and death  
We report significant reductions in incidence and risk of cardiovascular outcomes and 
mortality in patients with diabetes and the general population. Our analysis shows that 
the reduction in relative risk of fatal outcomes was not significantly different between 
patients with T1DM and matched controls, whereas patients with T2DM experienced 
a significantly lower relative risk reduction of fatal outcomes, compared to their 
matched controls. For non-fatal outcomes, the relative risk declined by roughly 20-
40% more in patients with diabetes, compared to matched controls. Patients with 
diabetes continue to display 2 to 4 times elevated risk for all cardiovascular outcomes 
and death, compared to the general population.  
Our findings are consistent with long-term trends in death and cardiovascular disease 
associated with diabetes in North America and Western Europe.36,38,56,57 The 
incidence and risk for heart failure did not decline significantly among patients with 
T1DM or their matched controls, while patients with T2DM experienced a greater 
risk reduction compared to matched controls. These findings are noteworthy since 
major risk factors for heart failure such as coronary heart disease, blood pressure 
levels and macroalbuminuria has decreased to a greater extent in patients with T1DM 
compared to patients with T2DM. There are several hypotheses for the increased risk 
for heart failure in patients with diabetes, our observations suggest that there are 
biological processes that we lack sufficient understanding of and treat less well. 
The reduction in cardiovascular outcomes and death reflects a combination of 
advances in clinical care and patient management of diabetes. Two research studies 
showed that the most attributable factors for the decline in CHD is improvement in 
cardiovascular risk factors, approximately 50% of the decline in this outcome was 
explained by risk factors.58,59 According to our data, rates of cardiovascular risk 
factors are gradually decreasing in patients with diabetes. Mean baseline glycated 
hemoglobin levels changed from 66.2 to 68.4 mmol/mol for type 1 diabetes, and from 
60.2 to 56.7 mmol/mol in patients with type 2 diabetes.  
Previous studies from the NDR has showed a significant decrease in glycated 
hemoglobin levels from 1998 to 2006, afterwards mean glycated hemoglobin levels 
began to increase in the type 1 diabetes population. The increase from 2006 and 
onwards is presumably a result of three influential randomized clinical trials, namely 
ACCORD, ADVANCE and VADT, whose result were likely extrapolated to patients 
with T1DM.53,60,61 Significant changes were also observed for low-density lipoprotein 
cholesterol, prevalence of macroalbuminuria, systolic blood pressure and increased 
usage of antihypertensive and statin medications.  
In summary, the study demonstrates that patients with diabetes, including the general 
population, have experienced a substantial reduction for cardiovascular disease and 
mortality during the last two decades. Interestingly, we observed a paradoxical 
finding between fatal and non-fatal events for patients with type 1 diabetes and type 2 
diabetes, compared to controls. Explaining the decrease of cardiovascular disease and 
mortality is imperative in order to understand success factors and plan for future risk 
mitigation strategies. 
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Multifactorial risk factor control in type 1 diabetes 
Our research group recently demonstrated the effect of having glycated hemoglobin 
levels below recommended guidelines levels <6.9% (<52mmol/mol) in type 1 
diabetes, and reported that these patients continued to display on average 2 times 
greater risk for cardiovascular events and death.27 Therefore, we selected 5 modifiable 
and traditional risk factors to assess whether maintaining these predictors within 
therapeutic target range would be associated with reduced or eliminated excess risk 
for cardiovascular events and death. We compared these results with matched controls 
from the general population. 
This study indicates that patients with T1DM with all risk factors at target level, still 
display 97% and 82% excess risk for heart failure and acute myocardial infarction, 
respectively. We observed a non-significant excess risk for all-cause mortality and 
stroke, the lack of statistical significance is most likely due to low statistical power. 
We identified a monotone association between the number of risk factor not at target 
levels and increased risk for outcomes. Poor risk factor control in patients with T1DM 
is associated with 7 to 15 times greater risk for outcomes, compared to matched 
controls. 
A possible explanation for the excess risk of myocardial infarction is hyperglycemia. 
For instance, patients with T1DM that have all risk factors within target range, still 
have on average higher glycated hemoglobin levels than matched controls without 
diabetes. Moreover, recommended target levels for glycated hemoglobin in patients 
with T1DM is still higher than the average glycated hemoglobin level in an individual 
without diabetes. Hyperglycemia accelerates the atherosclerotic process in coronary 
arteries and the average duration of diabetes in this study is 17 years at baseline, 
meaning that all study participants with diabetes have been exposed to, at least, 
slightly elevated glycated hemoglobin levels for many years.  
The abovementioned hypothesis is also applicable to our results for heart failure. 
Recent evidence suggests that hyperglycemia leads to heart failure through numerous 
mechanisms. Elevated blood glucose levels leads to the development of coronary 
heart disease, acute myocardial infarction, hypertension and macroalbuminuria that all 
contribute to the development to heart failure. In addition to these pathophysiological 
processes, hyperglycemia could also be a causal risk factor for heart failure. 
Molecular research indicates that hyperglycemia leads to interstitiell fibrotic 
remodeling of the myocardium, a condition that is associated with diastolic 
dysfunction and eventually heart failure. 
Another possible explanation for the increased risk of myocardial infarction and heart 
failure could be the residual risk observed in diabetics with hypertension and 
hyperlipidemia that were treated to target levels with statins and antihypertensive 
medications. Research suggests that inflammation and perhaps other processes could 
explain the residual risk in patients with risk factor control as a result of 
pharmacological treatment. Our study suggests that multifactorial risk factor control 
and perhaps intensive risk factor therapy is necessary to further reduce or eliminate 
excess risk for myocardial infarction and heart failure in patients with T1DM. The 
increased use of lipid lowering treatments, antihypertensive medication and insulin 
pumps will likely reduce the excess risk of all cardiovascular outcomes, including 
heart failure. 
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A holistic approach to risk factors in type 2 diabetes 
In this comprehensive epidemiological study we report that multifactorial risk factor 
control in patients with T2DM is associated with, at most, marginally increased risk 
for cardiovascular events and death, compared to the general population. Our analysis 
even indicates that attaining all 5 selected risk factors at target level can eliminate 
excess risk for myocardial infarction.  
Interestingly, we observe a stepwise association between younger age, increasing 
numbers of risk factors at baseline, and greater risk for events. This emphasizes the 
importance of multifactorial risk factor control and intensive risk factor therapy in 
younger individuals (<55 years of age) with T2DM. There is still an elevated risk for 
heart failure in patients with T2DM, even with all 5 risk factors at target level. Our 
analysis of multifactorial risk factor control does not specify which risk factor that is 
most important to control for preventing future cardiovascular disease and death 
among patients with T2DM. Therefore, we sought to investigate the strength of 
association for risk factors to determine which predictor that contributes most to the 
outcomes.  
The results show that physical activity, smoking, glycated hemoglobin, systolic blood 
pressure and low-density lipoprotein cholesterol contributes most to cardiovascular 
events and death. This analysis reveals several interesting pathophysiological 
differences between these outcomes. For instance, glycated hemoglobin is the 
strongest predictor for myocardial infarction and stroke, followed by systolic blood 
pressure and low-density lipoprotein cholesterol. Moreover, smoking, physical 
activity, marital status followed by glycated hemoglobin, seems to be the most 
important risk factor for death, whereas body mass index, glycated hemoglobin and 
physical activity are the strongest risk factors for heart failure. Clinical studies that 
have investigated the effect of increased physical activity have yet failed to 
demonstrate a beneficial effect from increased physical activity level. Nevertheless, 
epidemiological studies repeatedly demonstrate the importance of physical activity 
level.62-64  
The most important risk factors for heart failure are atrial fibrillation, body mass 
index, glycated hemoglobin and renal function. In our complementary analysis we 
studied a population without atrial fibrillation at baseline, which showed that body 
mass index is the strongest predictor, followed by glycated hemoglobin and physical 
activity, suggesting that a cardio-renal mechanism contributes to heart failure in 
patients with T2DM. Overweight and obesity, along with elevated glycated 
hemoglobin levels, leads to increasing hemodynamic stress through greater 
hemodynamic load, fluid retention, weight gain and electrolyte disorders.  
In our final research question regarding risk factors in patients with T2DM, we 
investigated the possibilities to reduce risk with lower levels than recommended target 
levels for the selected risk factors, glycated hemoglobin, systolic blood pressure and 
low-density lipoprotein cholesterol. Our results show that lower levels for systolic 
blood pressure is associated with lower levels for cardiovascular outcomes and death. 
The SPRING study and observational studies have showed that systolic blood 
pressure levels below target levels results in reduced risk for outcomes. The 
ACCORD blood pressure trial examined systolic blood pressure levels <120 mmHg 
vs. <140 mmHg, without a significant effect on intensive blood pressure control.53,65-
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In this article, we attempted to answer fundamental questions regarding risk factors 
for patients with T2DM. In summary, our findings suggest that multifactorial risk 
factor control is imperative for reducing excess risk for cardiovascular events and 
death, moreover, intensive multifactorial risk factor control seems even more 
important for young individuals with T2DM. The strongest risk factors for outcomes 
were physical activity, smoking, glycated hemoglobin, systolic blood pressure and 
low-density lipoprotein cholesterol. Our real-world data analysis shows that lower 
levels for glycated hemoglobin, systolic blood pressure and low-density lipoprotein 
cholesterol, than recommended target levels are associated with reduced risk for 
outcomes. 
 
Age at onset of type 1 diabetes 
Age of onset is a presumably an important variable for cardiovascular disease and 
death that caries information about important factors such as total glycemic load, 
varying autoimmune activity, genetic differences and differences in clinical care due 
to age.  
Therefore, we investigated the association of age at onset of disease in patients with 
T1DM. We noticed substantial differences in risk between different groups of age at 
onset. Patients with T1DM with disease onset before 10 years of age had 30 times 
greater risk of AMI, whereas women with T1DM had 60 times increased risk for 
CHD and 90 times increased risk for AMI.  
Harjutsalo et al, has studied the effect of early-onset (0-14 years) and late onset (15-
29 years) type 1 diabetes and observed that early-onset T1DM is associated with 
roughly 3 times increased risk for CHD than those with late-onset T1DM.68 Our study 
reveals an interesting finding, T1DM seems to be particularly associated with 
accelerated atherosclerosis of the coronary arteries and women seem to have highest 
risk for this outcome.  
Research shows that early-onset T1DM is associated with more aggressive insulitis 
and fewer insulin-producing beta-cells at disease onset.69 The strong relationship 
between cardiovascular disease, particularly coronary heart disease suggests that 
patients with T1DM that reach 30-40 years of age should be considered for lipid 
lowering treatment. Treatment of risk factors glycated hemoglobin, blood pressure 
and dyslipidemia should perhaps be viewed differently in patients with early-onset 
T1DM. Our results indicate that age at onset of T1DM is an essential factor that 
should be considered in all future risk mitigation strategies for patients with type 1 
diabetes. 
 
Importance of risk factors in type 1 diabetes 
In this study, we combined traditional cox regression with modern machine learning 
analyses to assess the relative importance of risk factors in patients with T1DM.70-72 
We incorporated the machine learning models for several reasons such as increased 
robustness, precision but more importantly the advantage of including higher-
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dimension interactions between multiple predictors, which has to be specified in the 
cox regression.  
Our results show that glycated hemoglobin, renal function, duration of diabetes, LDL-
C and systolic blood pressure are the most important predictors for cardiovascular 
events and death in patients with T1DM. Our results suggest different 
pathophysiological processes for the development of these outcomes considering the 
variability in the strength of association of risk factors. Glycated hemoglobin and 
albuminuria were the strongest predictors for mortality and heart failure, in contrast to 
myocardial infarction and stroke, where conventional cardiovascular risk factors such 
as LDL-C, glycated hemoglobin and systolic blood pressure proved to be the most 
important predictors. 
Our analyses suggest that albuminuria and duration of diabetes is in part explained by 
the integration of several inter-related pathophysiological mediators, for instance, age, 
HbA1c and blood pressure. Albuminuria was associated with 2- to 4-times greater 
risk for death and cardiovascular outcomes. Each mmol/mol higher HbA1c was 
associated with 2% increased relative risk for death, or 23% relative risk per 1% 
higher HbA1c. 
According to our analyses of optimal levels, glycated hemoglobin, systolic blood 
pressure and LDL-C display almost a linear relationship for risk of stroke and AMI. 
The present analysis shows that LDL-C is a strong predictor for AMI, stroke and HF, 
demonstrating approximately 35-50% higher relative risk for each mmol/l increase in 
LDL-C. This is an important finding since it further substantiates the importance of 
lipid lowering treatment in patients with T1DM.  
 
Strengths and limitations of the studies 
All studies in this thesis are based on observational studies from the national diabetes 
register. In these studies, virtually all patients with type 1 diabetes and type 2 diabetes 
in Sweden are included, with information available on comorbidities, medications and 
risk factors.  
We use imputation techniques to fill missing data for patients in order to avoid 
selection bias and increase statistical power. All studies are based on the 
epidemiological definition of type 1 diabetes and type 2 diabetes. These definitions 
are well validated and there is a strong concordance between the epidemiological 
definition and a clinician’s classification. We use both novel and conventional 
statistical methods. All studies are based on baseline characteristics to model long-
term outcomes, it is likely that time-updated models would have yielded more 
accurate risk associations, but our statistical approach decreases the risk of reverse 
causation biasing the results.  
These studies included several risk factors in most models, however we are aware that 
it is impossible to completely overcome the limitation of residual confounding. In our 
studies on multifactorial risk factor control we know that we could not distinguish 
between patients that attained risk factors within target level by means of medical 
treatment or patients that were within target range without any specific intervention. It 
is conceivable that our models are somewhat affected by reverse causation, we apply 
different modeling strategies to limit the influence of this.  
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CONCLUSIONS 
The incidence and risk of cardiovascular disease and death has decreased substantially 
in patients with diabetes and the general population. The risk for non-fatal outcomes 
has decreased more among patients with diabetes, compared to controls. Interestingly, 
fatal outcomes declined more in matched controls than patients with T2DM, whereas 
patients with T1DM experienced a risk reduction for fatal outcomes similar to 
matched controls. Still, patients with diabetes continue to display 2 to 4 times greater 
risk of cardiovascular outcomes and mortality, compared to the general population. 
The relative risk of heart failure decreased less compared to the other outcomes over 
the study period, both in patients with diabetes and matched controls. 
Multifactorial risk factor control is associated with significant risk reduction for 
cardiovascular events and death among patients with T1DM. Attaining all 5 selected 
risk factors within target range still results in 97% and 82% excess risk for heart 
failure and acute myocardial infarction, respectively. Patients with T1DM and poor 
risk factor control have several hundred percent-elevated risk compared to matched 
controls.  
Multifactorial risk factor control in patients with T2DM is associated with 
significantly lower risk for cardiovascular disease and outcomes. Patients with T2DM 
and all risk factors within therapeutic target range had, at most, 10% elevated risk for 
outcomes, compared to controls. Patients with optimal risk factor control had 16% 
lower risk for myocardial infarction, compared to the general population. We 
observed a monotone relationship between increasing number of risk factors not 
within target range, and increased risk for outcomes. Moreover, we noticed a stepwise 
association between age at baseline and risk for outcomes, younger at baseline is 
associated with increasing risk for outcomes. 
The strongest predictors for cardiovascular events and death in type 2 diabetes were 
the following: age, physical activity level, glycated hemoglobin, systolic blood 
pressure, smoking and low-density lipoprotein cholesterol. Our analyses suggests that 
these outcomes have different pathophysiological processes since the strength of 
association analysis shows differing results for each outcome, however, the strongest 
risk factors for myocardial infarction and stroke were fairly similar. Lower levels for 
glycated hemoglobin, systolic blood pressure and low-density lipoprotein cholesterol, 
than current guideline levels is associated with lower risk for outcomes. 
Age at onset of typ 1 diabetes is an important predictor that should be incorporated in 
future risk mitigation strategies since the variable is highly associated with future 
cardiovascular disease, particularly acute myocardial infarction. Women with T1DM 
have particularly high risk for cardiovascular disease. 
The strongest risk factors for type 1 diabetes are the following: age, glycated 
hemoglobin, albuminuria, duration of diabetes, low-density lipoprotein cholesterol 
and systolic blood pressure. Glycated hemoglobin is a strong predictor, and its 
association is most likely integrated with age, albuminuria or duration of diabetes. 
LDL-C is a stronger predictor than previously appreciated with approximately 35-
50% elevated risk for each mmol/l increase in LDL-C. For the three selected risk 
factors, we noticed almost a linear relationship between higher levels than 
recommended guideline levels and higher risk for outcomes. Our machine learning 
analyses reveals that age and duration of increasing are presumably strong predictors 
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since the effect of glycated hemoglobin, systolic blood pressure and low-density 
lipoprotein cholesterol is likely integrated in those risk factors.  
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FUTURE PERSPECTIVES 
The present thesis shows large reductions in cardiovascular disease and mortality 
among patients with diabetes and for the general population. Multifactorial risk factor 
control was associated with substantial reduction in excess risk for complications 
among patients with type 1 diabetes and type 2 diabetes, compared to the general 
population.  
Future research, preferably clinical trials, is warranted to determine the effect of 
multifactorial risk factor intervention, compared to standard care. This thesis attempts 
to further the understanding of relative risk for heart failure in patients with diabetes 
and the general population. Still, there is great demand for further research on the 
relationship between heart failure and diabetes.  
Moreover, our analyses reveal large variations in risk of outcomes between different 
age groups. The health care system and research community should investigate the 
effect of different risk mitigation strategies in order to reduce the large excess risk in 
younger individuals with diabetes. 
The relative importance analyses indicate that risk factors contribute to cardiovascular 
outcomes and death in different ways. The strength of association for risk factors 
differ not only for outcomes but also between type 1 diabetes and type 2 diabetes. 
Cardiometabolic risk factors contribute the most to acute myocardial infarction and 
stroke, whereas risk factors for heart failure and death differ from other outcomes. As 
such, the analysis suggests different pathophysiological pathways for the development 
of cardiovascular disease, heart failure and death. Forthcoming research should 
combine clinical data, bioimaging and genetics to increase our understanding of 
diabetes-related complications. 
Finally, recent clinical trials along with our research indicate that optimal levels for 
risk factors are perhaps lower levels than current therapeutic guideline levels. Also, 
optimal levels for risk factors presumably vary between different age groups. 
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